Torsten Willert

Torsten Willert

Auto-generated profile, based on publicly available information

Torsten Willert

Sirion Biotech GmbH, Planegg-Martinsried, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
DBDitte Rahbæk Boilesen
Ditte Rahbæk Boilesen
PNPatrick Neckermann
Patrick Neckermann
TWTorsten Willert
Torsten Willert
MMMikkel Dons Müller
Mikkel Dons Müller
SSSilke Schrödel
Silke Schrödel
PHPeter Johannes Holst
Peter Johannes Holst
Human papillomavirus (HPV) infections are the main cause of cervical and oropharyngeal cancers. As prophylactic vaccines have no curative effect, an efficient therapy would be highly desired. Most therapeutic vaccine candidates target only a small subset of HPV regulatory proteins, namely, E6 and E7, and are therefore restricted in the breadth of their immune response. However, research has suggested E1 and E2 as promising targets to fight HPV+ cancer. Here, we report the design of adenoviral vectors efficiently expressing HPV16 E1 and E2 in addition to transformation-deficient E6 and E7. Vaccination elicited vigorous CD4+ and CD8+ T-cell responses against all encoded HPV16 proteins in outbred mice and against E1 and E7 in C57BL/6 mice. Therapeutic vaccination of C3 tumor-bearing mice led to significantly reduced tumor growth and enhanced survival for both small and established tumors. Tumor biopsies revealed increased numbers of tumor-infiltrating CD8+ T cells in treated mice. Cisplatin enhanced the effect of therapeutic vaccination, accompanied by enhanced infiltration of dendritic cells into the tumor. CD8+ T cells were identified as effector cells in T-cell depletion assays, seemingly under regulation by FoxP3+CD4+ regulatory T cells. Finally, therapeutic vaccination with Ad-Ii-E1E2E6E7 exhibited significantly enhanced survival compared with vaccination with two peptides each harboring a known E6/E7 epitope. We hypothesize that this difference could be due to the induction of additional T-cell responses against E1. These results support the use of this novel vaccine candidate targeting an extended set of antigens (Ad-Ii-E1E2E6E7), in combination with cisplatin, as an advanced strategy to combat HPV+ cancers.

26 November 2025
Verified
Other
Open access
PDF file
DBDitte Rahbæk Boilesen
Ditte Rahbæk Boilesen
PNPatrick Neckermann
Patrick Neckermann
TWTorsten Willert
Torsten Willert
MMMikkel Dons Müller
Mikkel Dons Müller
SSSilke Schrödel
Silke Schrödel
PHPeter Johannes Holst
Peter Johannes Holst
Supplementary Table 1, Supplementary Figures 1-7

26 November 2025
Verified
Other
Open access
DBDitte Rahbæk Boilesen
Ditte Rahbæk Boilesen
PNPatrick Neckermann
Patrick Neckermann
TWTorsten Willert
Torsten Willert
MMMikkel Dons Müller
Mikkel Dons Müller
SSSilke Schrödel
Silke Schrödel
PHPeter Johannes Holst
Peter Johannes Holst
Human papillomavirus (HPV) infections are the main cause of cervical and oropharyngeal cancers. As prophylactic vaccines have no curative effect, an efficient therapy would be highly desired. Most therapeutic vaccine candidates target only a small subset of HPV regulatory proteins, namely, E6 and E7, and are therefore restricted in the breadth of their immune response. However, research has suggested E1 and E2 as promising targets to fight HPV+ cancer. Here, we report the design of adenoviral vectors efficiently expressing HPV16 E1 and E2 in addition to transformation-deficient E6 and E7. Vaccination elicited vigorous CD4+ and CD8+ T-cell responses against all encoded HPV16 proteins in outbred mice and against E1 and E7 in C57BL/6 mice. Therapeutic vaccination of C3 tumor-bearing mice led to significantly reduced tumor growth and enhanced survival for both small and established tumors. Tumor biopsies revealed increased numbers of tumor-infiltrating CD8+ T cells in treated mice. Cisplatin enhanced the effect of therapeutic vaccination, accompanied by enhanced infiltration of dendritic cells into the tumor. CD8+ T cells were identified as effector cells in T-cell depletion assays, seemingly under regulation by FoxP3+CD4+ regulatory T cells. Finally, therapeutic vaccination with Ad-Ii-E1E2E6E7 exhibited significantly enhanced survival compared with vaccination with two peptides each harboring a known E6/E7 epitope. We hypothesize that this difference could be due to the induction of additional T-cell responses against E1. These results support the use of this novel vaccine candidate targeting an extended set of antigens (Ad-Ii-E1E2E6E7), in combination with cisplatin, as an advanced strategy to combat HPV+ cancers.

4 April 2023
Verified
Other
Open access
DBDitte Rahbæk Boilesen
Ditte Rahbæk Boilesen
PNPatrick Neckermann
Patrick Neckermann
TWTorsten Willert
Torsten Willert
MMMikkel Dons Müller
Mikkel Dons Müller
SSSilke Schrödel
Silke Schrödel
PHPeter Johannes Holst
Peter Johannes Holst
Supplementary Table 1, Supplementary Figures 1-7

4 April 2023
Verified
Other
Open access
DBDitte Rahbæk Boilesen
Ditte Rahbæk Boilesen
PNPatrick Neckermann
Patrick Neckermann
TWTorsten Willert
Torsten Willert
MMMikkel Dons Müller
Mikkel Dons Müller
SSSilke Schrödel
Silke Schrödel
PHPeter Johannes Holst
Peter Johannes Holst
Supplementary Table 1, Supplementary Figures 1-7

4 April 2023
Verified
Other
Open access
DBDitte Rahbæk Boilesen
Ditte Rahbæk Boilesen
PNPatrick Neckermann
Patrick Neckermann
TWTorsten Willert
Torsten Willert
MMMikkel Dons Müller
Mikkel Dons Müller
SSSilke Schrödel
Silke Schrödel
PHPeter Johannes Holst
Peter Johannes Holst
Human papillomavirus (HPV) infections are the main cause of cervical and oropharyngeal cancers. As prophylactic vaccines have no curative effect, an efficient therapy would be highly desired. Most therapeutic vaccine candidates target only a small subset of HPV regulatory proteins, namely, E6 and E7, and are therefore restricted in the breadth of their immune response. However, research has suggested E1 and E2 as promising targets to fight HPV+ cancer. Here, we report the design of adenoviral vectors efficiently expressing HPV16 E1 and E2 in addition to transformation-deficient E6 and E7. Vaccination elicited vigorous CD4+ and CD8+ T-cell responses against all encoded HPV16 proteins in outbred mice and against E1 and E7 in C57BL/6 mice. Therapeutic vaccination of C3 tumor-bearing mice led to significantly reduced tumor growth and enhanced survival for both small and established tumors. Tumor biopsies revealed increased numbers of tumor-infiltrating CD8+ T cells in treated mice. Cisplatin enhanced the effect of therapeutic vaccination, accompanied by enhanced infiltration of dendritic cells into the tumor. CD8+ T cells were identified as effector cells in T-cell depletion assays, seemingly under regulation by FoxP3+CD4+ regulatory T cells. Finally, therapeutic vaccination with Ad-Ii-E1E2E6E7 exhibited significantly enhanced survival compared with vaccination with two peptides each harboring a known E6/E7 epitope. We hypothesize that this difference could be due to the induction of additional T-cell responses against E1. These results support the use of this novel vaccine candidate targeting an extended set of antigens (Ad-Ii-E1E2E6E7), in combination with cisplatin, as an advanced strategy to combat HPV+ cancers.